

23 RECOMMENDATIONS IN MODELLING PRECISION MEDICINE:

LEARNING FROM CASE STUDIES IN TUMOUR AGNOSTIC TREATMENTS, DPYD GENOTYPING AND MATURITY ONSET DIABETES OF THE YOUNG

Matthijs Versteegh, PhD

Versteegh@imta.eur.nl

THE HECOPERMED PROJECT

'Health Economics for Personalised Medicine' (HEcoPerMed) aims to identify the **best health economic modelling** and **payment strategies** for personalised medicine in order to **recognise valuable interventions** and **stimulate their adoption** across the EU.



Erasmus School of
Health Policy
& Management



syreon
Research Institute



Doris Schartinger



Maren Walgenbach



Maureen Rutten-van
Mülken



Balázs Nagy



Sarah Wordsworth



Manuela Kienegger



Wolfgang Ballensiefen



Heleen Vellekoop



László Szilberhorn



Rositsa Koleva Kolarova



Andreas Weinhäusel



Hecopermed.eu

Simone Huygens



Tamás Zelei



Apostolos Tsiachristas




Günter Schreier













Matthijs Versteegh

OVERVIEW HECOPERMED PROJECT



WP1
“Modelling Guidance”

Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine

Heleen Vellekoop¹  · Simone Huygens¹  · Matthijs Versteegh¹  · László Szilberhorn²  · Tamás Zelei²  ·
Balázs Nagy²  · Rositsa Koleva-Kolarova³  · Apostolos Tsiachristas³  · Sarah Wordsworth³  ·
Maureen Rutten-van Mölken^{1,4}  on behalf of the HEcoPerMed Consortium

Accepted: 15 February 2021 / Published online: 16 April 2021
© The Author(s) 2021

2. Application of best practice health economic modelling in personalised medicine

- Select three case studies in the area of personalised medicine
- Develop cost-effectiveness and budget impact models by using guidance developed in WP1
- Test and validate the applicability of the developed guidance and suggest adjustments



Health economic modelling of tumour agnostic treatments for NTRK gene fusion-positive (NTRK+) cancers



Health economic modelling of DPYD genotyping prior to fluoropyrimidine-based chemotherapy (ToxNav)



Health economic modelling of maturity onset diabetes of the young

YOUR INPUT IS IN POLLING
QUESTIONS IS APPRECIATED



This project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 824997.



THANK YOU FOR ATTENDING



This project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 824997.

